4007787550
|
 |
||||||||||||||
| 貨號(hào) | 品名 | 規(guī)格 | 包裝 | 單價(jià) | 貨期 | 庫(kù)存 |
| JD200512094618 | 維多珠單抗 | 99.64% | 5mg | 17600元 | 咨詢客服 | 3天 |
| JD200512094431 | 維多珠單抗 | 99.64% | 1mg | 5800元 | 咨詢客服 | 3天 |
| 性狀： | Vedolizumab是一種靶向α4β7整聯(lián)蛋白 (integrin) 的人源化單克隆抗體，用來(lái)治療潰瘍性結(jié)腸炎和克羅恩病。 |
| 質(zhì)量標(biāo)準(zhǔn)： | Description Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease. IC50 & Target |
| 貯存： | References [1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. [2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7( |
